Research progress of PD-1/PD-L1 inhibitors in the treatment of advanced bladder cancer
10.3760/cma.j.cn101721-20230702-000234
- VernacularTitle:程序性细胞死亡蛋白1及程序性细胞死亡配体1抑制剂在晚期膀胱癌治疗中的研究进展
- Author:
Jiahao SU
1
;
Mingqian YANG
;
Chaolong LIANG
;
Jian WANG
Author Information
1. 广东医科大学附属医院泌尿外科，湛江 524000
- Keywords:
Advanced bladder cancer;
Urothelial carcinoma;
Immune checkpoint inhibitors;
Programmed cell death protein 1;
Programmed death ligand 1
- From:
Clinical Medicine of China
2023;39(5):394-400
- CountryChina
- Language:Chinese
-
Abstract:
Bladder cancer is one of the most common malignant tumors of the urinary system, among which urothelial carcinoma is the main one. The traditional treatment methods are mainly surgical resection and chemotherapy, but the treatment effect of advanced patients is not good, and the prognosis is poor. In recent years, with the development of immune checkpoint inhibitors, there are many treatment options that are more effective than traditional therapies. Programmed cell death protein 1 (PD-1)and programmed cell death ligand 1(PD-L1)inhibitors stop the negative regulation of the immune system by blocking the binding of PD-1 and PD-L1, thereby enhancing the anti-tumor activity of the body's immune system. This article mainly reviews the efficacy and safety of PD-1/PD-L1 inhibitors commonly used in the clinical treatment of locally advanced or metastatic urinary tract carcinoma of the bladder.
